Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | CD38 | P28907 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616433 | 0.84 | GBA1 (0.39) | PFKFB3GBA1PARP1HDAC6KCNN3 | |
| SCHEMBL1615739 | 0.82 | ADRA1A (0.44) | GBA1PARP1HDAC6KCNN3JAK2 | |
| SCHEMBL1616564 | 0.81 | TAAR1 (0.40) | GBA1PARP1HDAC6KCNN3JAK2 | |
| SCHEMBL1616104 | 0.80 | HDAC6 (0.38) | GBA1PARP1HDAC6KCNN3JAK2 | |
| SCHEMBL3844986 | 0.80 | PDPK1 (0.47) | PFKFB3GBA1HDAC6KCNN3JAK2 | |
| SCHEMBL1615636 | 0.79 | NTRK1 (0.39) | PFKFB3GBA1PARP1CYP3A4CYP2C9 | |
| SCHEMBL1616340 | 0.79 | PDE10A (0.41) | PFKFB3GBA1CYP3A4CYP2C9JAK2 | |
| SCHEMBL1616589 | 0.79 | GBA1 (0.50) | GBA1CYP3A4CYP2C9JAK2JAK3 | |
| SCHEMBL1616542 | 0.78 | GBA1 (0.40) | PFKFB3GBA1CYP3A4CYP2C9JAK2 | |
| SCHEMBL2248366 | 0.78 | GBA1 (0.39) | PFKFB3GBA1PARP1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923561-B2 | Quinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2099763-B1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-2099763-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20080146567-A1 | QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | US | disclosed |
| WO-2008068157-A1 | 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146567-A1 | QUINOLINES | HTR5A, HTR2B, HTR2C | PFKFB3 4177/4885GBA1 662/4885CD38 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.